Related Experiment Video
Updated: Aug 20, 2025
Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
Published on: April 2, 2021
Retinopathy of prematurity
Olaf Dammann1,2,3, M Elizabeth Hartnett4, Andreas Stahl5
1Tufts University School of Medicine, Department of Public Health & Community Medicine, MA, Boston, USA.
Insights
Retinopathy of prematurity (ROP) is a serious eye condition in premature infants. Recent advancements include a new classification system and anti-vascular endothelial growth factor (VEGF) treatments, though research into their long-term effects is ongoing.
Area of Science:
- Ophthalmology
- Neonatology
- Developmental Biology
Background:
- Retinopathy of prematurity (ROP) is a significant cause of vision loss in premature infants.
- It is a complex neurovascular disorder affecting retinal development.
Purpose of the Study:
- To provide a concise review of current knowledge on ROP diagnosis, etiology, pathogenesis, intervention, and outcomes.
- To discuss advancements in ROP classification and treatment with anti-VEGF agents.
- To explore the benefits and risks of anti-VEGF therapy and identify future research directions.
Main Methods:
- Literature review and synthesis of current research on ROP.
- Analysis of the International Classification of Retinopathy of Prematurity, Third Edition.
- Evaluation of anti-vascular endothelial growth factor (VEGF) treatment strategies.
Main Results:
- Major advancements include the updated International Classification of ROP, Third Edition.
- Anti-VEGF agents represent a significant new treatment modality for severe ROP.
- Improved understanding of ROP pathophysiology informs treatment decisions.
Conclusions:
- Anti-VEGF therapy offers benefits but also carries risks that require careful consideration.
- Further research is needed to fully understand the long-term implications of anti-VEGF treatment in ROP.
- Continued investigation into ROP pathophysiology and treatment is essential.
Abstract:
Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In this concise review we discuss our current knowledge about diagnosis, etiology, pathogenesis, intervention, and outcomes of the disease. Major advancements have been made both in categorizing the disease in the new International Classification of Retinopathy of Prematurity, Third Edition classification and in treating severe ROP with anti-vascular endothelial growth factor (VEGF) agents. New development always creates new questions and opens up new areas of research. We will discuss in this review both the benefits and downsides of the new anti-VEGF treatment approaches in ROP, especially in light of our improved understanding of the underlying ROP pathophysiology. We also offer pointers to areas where more research is needed. WHAT THIS PAPER ADDS: Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti-vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified.
Related Concept Videos
01:32The Retina
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...